What changed
Curated milestones for peptides covered on this site — approvals, trial readouts, filings. Newest first.
This is a hand-curated log of scientific and regulatory milestones. For a daily feed of external headlines, see the News page.
FDA approves Foundayo (orforglipron) — first oral GLP-1 weight-loss pill
No food or water timing restrictions. Approved under the Commissioner's National Priority Voucher pilot — fastest NME approval since 2002.
FDA expands Imcivree to acquired hypothalamic obesity (ages 4+)
Phase 3 TRANSCEND: −18.4% placebo-adjusted BMI reduction at 52 weeks. Third indication for setmelanotide.
Boehringer Ingelheim files NDA for survodutide (obesity)
Glucagon/GLP-1 dual agonist. Also Phase 3 in MASH (LIVERAGE). Breakthrough Therapy designation.
Novo Nordisk files NDA for CagriSema (cagrilintide + semaglutide)
First once-weekly GLP-1 + amylin fixed-dose combination submitted for FDA review. REDEFINE 1 showed ~23% mean weight loss.
Survodutide SYNCHRONIZE-1/2 meet primary endpoints
Phase 3 obesity studies hit weight-loss targets. Published Lancet D&E Jan 2026. Triggers NDA filing (Feb 2026).
TRIUMPH-4 positive: retatrutide delivers 28.7% weight loss + knee OA pain relief
First successful Phase 3 readout. WOMAC pain −75.8% at 68 weeks. Seven further Phase 3 readouts expected in 2026.
Novo reports amycretin Phase 2 T2D: −14.5% (SC) / −10.1% (oral) weight loss
Dose-dependent HbA1c reduction up to −1.8%. Phase 3 programme planned for 2026.
FDA grants Wegovy accelerated approval for noncirrhotic MASH (F2–F3)
Second drug ever approved for MASH. Based on ESSENCE Phase 3 data showing fibrosis improvement without worsening of steatohepatitis.
FDA approves Zepbound for moderate-to-severe obstructive sleep apnea
First and only drug for OSA in adults with obesity. Based on two Phase 3 studies of 469 adults.
Lincoff et al. publish SELECT — semaglutide cuts MACE by 20% in obesity without diabetes
17,604 adults. Cardiovascular benefit independent of weight loss — reshaped the obesity-drug narrative.
Jastreboff et al. publish retatrutide Phase 2 — −24.2% body weight
Triple GIP/GLP-1/glucagon agonist produced the largest 48-week weight loss reported at the time.
Jastreboff et al. publish SURMOUNT-1 — tirzepatide in obesity
Up to −22.5% body weight at 72 weeks. First time a GLP-1 class drug crossed the 20% barrier.
Wilding et al. publish STEP 1 — semaglutide 2.4 mg in obesity
Mean −14.9% body weight at 68 weeks vs −2.4% placebo. Launched the modern GLP-1 obesity era.
FDA approves Imcivree (setmelanotide) for POMC/PCSK1/LEPR deficiency
First approved MC4R agonist for rare monogenic obesity. Rhythm Pharmaceuticals.